Comment: PARP inhibitors for advanced prostate cancer

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

Comment: CDK4/6 inhibitors in advanced breast cancer

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

Ovarian highlights from ESMO 2019

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Comment: Osimertinib for EGFR-mutation positive NSCLC